Related Experiment Video
Updated: May 29, 2026

Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice
Published on: March 11, 2020
Translating glutamate: from pathophysiology to treatment
Daniel C Javitt1, Darryle Schoepp, Peter W Kalivas
1Translational Schizophrenia Research Center, Nathan Kline Institute/Columbia University College of Physicians and Surgeons, New York, NY 10032, USA. javitt@nki.rfmh.org
Glutamate neurotransmission is key in brain function and neuropsychiatric disorders like schizophrenia and depression. Despite advances, developing effective treatments requires better biomarkers and collaborative research efforts.
Area of Science:
- Neuroscience
- Neurobiology
- Psychiatry
Background:
- Glutamate is the primary excitatory neurotransmitter in the mammalian brain.
- Dysregulation of glutamatergic function is linked to neuropsychiatric disorders such as schizophrenia, addiction, autism, and depression.
- Current understanding of these disorders has not yet led to FDA-approved treatments.
Purpose of the Study:
- To review recent advances in understanding the role of glutamate in neuropsychiatric disorders.
- To identify key barriers hindering the translation of basic research into clinical treatments.
- To highlight the need for enhanced collaborative efforts in drug development.
Main Methods:
- Review of an Institute of Medicine-sponsored meeting.
- Discussion of current glutamatergic theories in neuropsychiatric illness.
- Analysis of challenges in developing novel therapeutics and biomarkers.
Main Results:
- Significant progress has been made in understanding glutamatergic theories of neuropsychiatric disorders.
- Existing barriers include the need for improved therapeutic compounds, sensitive biomarkers for target engagement, and effective translational models.
- Unique collaborative models involving pharmaceutical companies, government agencies, and academic institutions are essential.
Conclusions:
- Advances in glutamatergic research offer new insights into neuropsychiatric disorders.
- Overcoming translational barriers requires innovation in biomarker development and collaborative research frameworks.
- Future progress necessitates integrated approaches to bridge the gap between basic science and clinical application.
Related Concept Videos
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Ligand-gated Ion Channels
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that include the...
Antiepileptic Drugs: Glutamate Antagonists
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Amino Acid Biosynthetic Pathways
Neurochemical Transmission: Sites of Drug Action

